Clinical trials: Antibody Response After Vaccination
Poliomyelitis, Vaccine Reaction
Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants
Eupolio is inactivated poliovirus vaccine (IPV). Major purpose of this study is to evaluate safety of Eupolio in 2,000 infants. In addition to the safety, long-term protection after completion of the three primary vaccinations…
- Trial name
- NCT05431933
- Testing
- Eupolio
- Where
- 10 sites in Philippines, Thailand
- Volunteers
- 2,001 people, healthy volunteers welcome
- Sponsor
- LG Chem
Meningococcal Disease
One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age
One year antibody persistence after the fourth dose boost or two catch-up doses administered starting from 12 months of age and to evaluate the response to a a third dose boost or two catch-up dose starting at 24 months of age.
- Trial name
- NCT01139021
- Testing
- rMenB+OMV NZ
- Where
- 19 sites in Czechia, Finland
- Volunteers
- 508 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
SARS-CoV-2
A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind
This study will investigate antibody levels with respect to time since receiving a COVID-19 booster shot. The study will be decentralized, where participants can complete all study tasks at home.
- Trial name
- disCOVEries (NCT05367908)
- Where
- United States
- Volunteers
- 1,501 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19 Vaccine
SARS-CoV-2 Antibody Response in Children Aged 5-11 Years Following Vaccination Against COVID-19
There are few data on the immunogenicity of the Pfizer-Biontec BNT162b2 vaccine for the prevention of COVID-19 disease and of side effects in children aged 5-11 years.
- Trial name
- NCT05175989
- Where
- Israel
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Rabin Medical Center
Covid19, Breakthrough Infection
Antibody After COVID-19 Vaccination
Chronic kidney disease (CKD) including patients on dialysis and kidney transplant recipients. represents the special subgroups of patients that required protection during the Severe Coronavirus Disease 2019 (COVID-19) pandemic…
- Conditions
- Covid19, Breakthrough Infection, CKD, Kidney Transplant
- Trial name
- NCT05057936
- Testing
- COVID vaccine
- Where
- Thailand
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Bangkok Metropolitan Administration Medical College and Vajira Hospital
Adverse Reaction to Cholera Vaccine, Cholera Vaccination Reaction
Extended Dose Intervals With Oral Cholera Vaccine in Cameroon
The primary aim of this project is to determine changes in the vibriocidal geometric mean titers (GMT) in subjects who receive the second dose of oral cholera vaccine (OCV) at different intervals: 2 weeks, 6 months, or 11 months…
- Trial name
- NCT03719066
- Testing
- killed whole cell oral cholera vaccine
- Where
- Cameroon
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
13-valent Pneumococcal Vaccine, Immunization
Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.
This is an open-label study (a study in which the doctors and participants know which drug or vaccine is being administered) in children who previously received a 4-dose series of a pneumococcal conjugate vaccine (PnC) during…
- Conditions
- 13-valent Pneumococcal Vaccine, Immunization, Safety, Antibody Response
- Trial name
- NCT01026038
- Testing
- 13-valent pneumococcal conjugate vaccine
- Where
- 25 sites in France
- Volunteers
- 263 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Aging
Beta-glucan and Immune Response to Influenza Vaccine
This trial in healthy adults will determine the effects of beta-glucan, a dietary fiber supplement isolated from baker's yeast, on immune response to the influenza vaccine.
- Trial name
- M-Unity (NCT05074303)
- Testing
- Influenza Vaccine, Beta-glucan
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- University of Florida
Prevention of Meningococcal Infection
Persistence of Antibody Response to N. Meningitidis Group C in Children
Persistence of Antibody Response to N. meningitidis Group C in Children
- Trial name
- NCT00316654
- Testing
- Meningococcal C conjugate vaccine
- Where
- 2 sites in Poland, Spain
- Volunteers
- 489 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Covid19, Vaccine Reaction
Protective Antibody Level After COVID-19 Vaccination Among Patients Under Hemodialysis
The aim of the study is to evaluate the level of neutralizing antibody against SARS-CoV-2 after COVID-19 vaccination in patients under hemodialysis.
- Conditions
- Covid19, Vaccine Reaction, Hemolysis, End-stage Renal Disease
- Trial name
- NCT04871945
- Testing
- Elecsys Anti-SARS-CoV-2 S (Roche Diagnostics GmbH, Mannheim, Germany), 2) ACCESS SARS-CoV-2 IgG II (Beckman Coulter, Inc. USA)
- Where
- South Korea
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Hanyang University Seoul Hospital
Antibody Response After Vaccination
Twinrix Alternative Schedule Study
To compare the efficiency of protection against hepatitis-B virus by administration of the combined vaccine against hepatitis A and B using the schedule 0-1-12 months against the schedule 0-1-6 months. 1.
- Trial name
- NCT00216229
- Testing
- Combined vaccine against hepatitis A and B (Twinrix)
- Where
- Belgium
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- IDEWE Occupational Health Services
Hepatitis B
Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers
The purpose of this study is to evaluate the persistence of anti-hepatitis B surface antigen (anti-HBs) antibodies 16, 17, 18, 19 and 20 years after administration of the first dose of the study vaccine.
- Trial name
- NCT00240500
- Testing
- Engerix™-B
- Where
- Thailand
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Meninigitis, Serogroup C
Follow-up Study on the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens 1 Month After the 4th Hexavac® Vaccination in Healthy Children, Who Participated in NeisVac-C Study 216
The primary aim of the study is to show that the antibody response to hepatitis B, acellular pertussis toxin and inactivated poliovirus antigens after the 4th vaccination with Hexavac® is not influenced by the concomitant…
- Trial name
- NCT00161941
- Where
- 11 sites in Austria, Germany
- Volunteers
- 321 people, healthy volunteers welcome
- Sponsor
- Pfizer
Meningococcal Disease, Infections, Meningococcal
A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)
The purpose of this study is to evaluate persistence of bactericidal antibodies for N. meningitidis serogroups A, C, W, and Y and serogroup B test strains approximately 4 years after primary vaccination in subjects who previously…
- Trial name
- NCT02451514
- Testing
- MenABCWY+OMV vaccine
- Where
- 7 sites in Chile, Colombia and 1 more
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Meningococcal
Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations
This is Phase IV, Open label, Multicenter study. Subject's parents and/or legal guardian will be provided information about the trial. If interested and if eligible, they will then be asked to provide signed informed consent.
- Trial name
- NCT02446691
- Testing
- MenACWY
- Where
- 6 sites in South Korea
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prevention of Meningococcal Infection
Persistence of Immune Response After Vaccination With MCC
Persistence of Immune response after vaccination with MCC
- Trial name
- NCT00310687
- Testing
- BLOOD DRAW
- Where
- United Kingdom
- Volunteers
- 1,244 people, healthy volunteers welcome
- Sponsor
- Novartis
HIV
Vaccination Response in ImmunoCompromised Host. Immune Response After Vaccination Against Pandemic A/H1N1 Influenza
As recommended by the Dutch Health Council, certain risk groups and health care workers in The Netherlands were vaccinated to prevent morbidity due to pandemic influenza A/H1N1.
- Trial name
- RICH-3 (NCT01066169)
- Testing
- Foceteria® (Novartis)
- Where
- Netherlands
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Measles, Mumps
Measles, Mumps, and Rubella (MMR) Immunity in College Students
This study will lay the foundation for determining the underlying reasons for lack of immunity to mumps that led to the 2006 mumps outbreak on college campuses in the Mid West, and it will assess the potential for similar…
- Conditions
- Measles, Mumps, Rubella
- Trial name
- NCT00962819
- Testing
- MMR vaccine
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Sri Edupuganti, MD MPH
HIV
MMR Vaccination Among HIV-infected Adults
This is a prevalence study of protective antibodies to measles, mumps, and rubella (MMR) in HIV-infected adults and HIV-uninfected controls.
- Trial name
- NCT02724852
- Testing
- 0.5 ml of MMR vaccine
- Where
- Thailand
- Volunteers
- 632 people, healthy volunteers welcome
- Sponsor
- Chiang Mai University
Infections, Meningococcal
Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents
The purpose of this study is to compare the persistence of 2 or 3 doses of the GSK MenABCWY vaccine, or 2 doses of GSK rMenB+OMV vaccine (Bexsero) administered to healthy adolescents at approximately 24 months after the last…
- Trial name
- NCT02946385
- Testing
- Meningococcal ABCWY Vaccine, Meningococcal B Recombinant vaccine
- Where
- 17 sites in Finland, Poland
- Volunteers
- 604 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline